BioNTech SE
Sector: Manufacturing
Industry: Pharmaceutical Products
118.14
-3.98
(-3.26%)
Volume:
695,445
52 week range:
76.53 - 131.49
Market Cap:
28.085M
Company Description:
BioNTech SE develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma. It also develops neoantigen specific immunotherapy, such as Autogene cevumeran (BNT122) and BNT141.